Navigation Links
Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Date:1/3/2012

AMSTERDAM, January 4, 2012 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its gene therapy program for the treatment of hemophilia B. Orphan designation in the U.S. could provide up to seven years market exclusivity on regulatory approval. Orphan designation for AMT's hemophilia program in the European Union was granted in November 2011.

AMT's hemophilia B program, which consists of an adeno-associated viral (AAV) vector containing the human factor IX gene, is being investigated in a Phase I/II study conducted by St. Jude's Children's Research Hospital (Memphis, USA) and University College London (UK). Promising data from an initial 6 patients, recently published in the New England Journal of Medicine (N Engl J Med 2011; 365:2357-2365), shows that gene therapy administration resulted in a reduced need for protein replacement treatment, the standard care for hemophilia patients.  AMT is preparing for additional clinical development work to establish safety, tolerability and proof-of-concept with a factor IX gene therapy produced using its proprietary AAV production system.

"U.S. orphan designation provides additional support for our hemophilia B gene therapy program and supplements the designation in the EU received in November," said Jörn Aldag, CEO of AMT. "The early clinical success seen with the program to date by our partners is very encouraging. We will build on this success in the coming months."  

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. AMT has a product pipeline of gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicl
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 /PRNewswire-iReach/ -- Think Drinks are a neuroscience-backed ... long term. They are the first functional focus beverage ... as an alternative to the temporary fix associated with ... on July 29, 2014, with hopes to raise $50,000 ... Photo - http://photos.prnewswire.com/prnh/20140723/129697 Think ...
(Date:7/23/2014)... , July 23, 2014  AuraSense Therapeutics, ... as gene regulatory and immunotherapeutic agents, announced ... joined AuraSense Therapeutics, executive leadership team as ... Prior to joining AuraSense Therapeutics, Mr. ... Financial Officer of Cellular Dynamics International Inc., ...
(Date:7/23/2014)... 2014 Shimadzu Scientific Instruments has ... analysis system developed jointly with Ajinomoto Co. Inc. ... analyze 38 amino acids in nine minutes, drastically ... high-speed analysis utilizing a fast application-specific column and ... analytical results even under conditions with difficult samples ...
(Date:7/23/2014)... Last year, Formedix celebrated its partnership ... of data management solutions for clinical trials. The company ... electronic data capture (EDC) and clinical data management. Formedix, ... tools added TrialMaster to its Transform for EDC product ... for TrialMaster, is being released this week, in response ...
Breaking Biology Technology:truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3
... to Reveal Successful Strategies for China, India at the PharmAsia... -- SAN FRANCISCO, October 13, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... Calif., Oct. 13 Biomerix Corporation ... Patent and Trademark Office (USPTO) has granted ... technology titled "Reticulated elastomeric matrices, their manufacture ... platform technology, the Biomerix Biomaterial™ is a ...
... RICHLAND, Washington A redesign of sodium-nickel chloride batteries ... with rechargeable batteries. Replacing their typical cylindrical shape with ... 30 percent more power at lower temperatures, according to ... October 8 issue of ECS Transactions , a ...
Cached Biology Technology:Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 2Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 3Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 4Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 5Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 6Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 7Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 8Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 9Biomerix Granted US Patent for Its Proprietary Biomaterial Platform Technology 2Planar power 2
(Date:7/23/2014)... a high health risk warning for Yellowknife and surrounding ... to forest fires. In the image taken by ... normal wind patterns. Fire is an obvious health ... not quite so obvious and its effects are insidious. ... (forest, brush, crop, structure, tires, waste or wood burning) ...
(Date:7/23/2014)... , , , , , ... , , , , ... prevent multiple chronic diseases and extend healthy lifespan. The idea, they argue, would be to target the... , ... , , , , , ... , , , , , , ...
(Date:7/23/2014)... TORONTO, July 23, 2014 Migratory songbirds are disappearing, ... as climate change, loss of habitat, acid rain and ... remained missing: where do these birds go once they ... be encountering along the way? , To answer this ... have created the first ever migratory connectivity map produced ...
Breaking Biology News(10 mins):Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5York University researchers use bird 'backpacks' to put wood thrushes migration on the map 2
... This release is available in German . ... the numerous biological functions of an organism are not regulated ... mechanisms exist that contribute to determining the fate of genes. ... even be passed on to subsequent generations to a certain ...
... University engineers have taken a first step toward a ... with heat administered from the end of a catheter. ... technically possible to treat brain tumors without the side ... chemotherapy or radiation. The bioengineers designed and built ...
... N.C. In 2004, researchers at the University of ... announced a crucial discovery in the understanding of cellular ... age, the expression of a key protein, called p16INK4a, ... is a tumor suppressor protein, cancer researchers are interested ...
Cached Biology News:New piece found in the puzzle of epigenetics 2Potential for non-invasive brain tumor treatment 2Test detects molecular marker of aging in humans 2
Anti 7H6 Antigen (tight-junction associated protein Antigen) Monoclonal Antibody 7H6...
... to ARG. Vasopressin The antibody ... Cells are found in the paraventricular ... found throughout the hypothalmus in rat ... Immunogen: Arginine ...
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Biology Products: